



PATENT NUMBER and ISSUE DATE

U.S. UTILITY Patent Application

"CONTINUING DATA VERIFIED: This application is a CON of 09/640,097 08/15/2000 PAT 6,384,059 which is a CON of 09/202,251 12/10/1998 PAT 6,150,380 which is a 371 of PCT/SE98/02028 11/10/1998 FOREIGN APPLICATIONS VERIFIED: G-PUB DO NOT PUBLISH	APPL NUM	FILING DATE		SUBCLASS		EXAMINER
FOREIGN APPLICATIONS VERIFIED: This application is a CON of 09/640,097 08/15/2000 PAT 6,384,059 which is a CON of 09/202,251 12/10/1998 PAT 6,150,380 which is a 371 of PCT/SE98/02028 11/10/1998 FOREIGN APPLICATIONS VERIFIED: Telephonology of the control of t	10076225	02/13/2002				
G-PUB DO NOT PUBLISH RESCIND reign priority claimed yes no ATTORNEY DOCKET NO USC 119 conditions met yes no I103326-0538 ILE: Crystalline form of omeprazole US DEPT. OF COMM.PAT. 8 TM-PTO 436L(Rev. 12-9 TCE OF ALLOWANCE MAILED ASSISTANT Examiner ASSISTANT Examiner Primary Examiner Primary Examiner Primary Examiner Primary Examiner WARNING: The information disclosed herein may be restricted. Us application Examiner WARNING: The information disclosed berein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Tith Sections 122, 181 and 368, Possessiog outside the U.S. Patent & Tradema	**CONTINUING This application which is a CON	DATA VERIFIED is a CON of 09/64 of 09/202,251 12/): 10,097 08 10/1998	6/15/2000 PAT PAT 6,150,380	6,384,0	
TLE : Crystalline form of omeprazole US DEPT. OF COMM.PAT. 8 TM-PTO-436L(Rev. 12-9 TCE OF ALLOWANCE MAILED Assistant Examiner ISSUE FEE DIAWING Primary Examiner TERMINAL PREPARED FOR ISSUE Application Examiner WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title Sections 122, 181 and 368, Possession outside the U.S. Patent & Tradema	PG-PUB DO NO	T PUBLISH -	u yes (□ no		ATTORNEY DOCKET NO
TCE OF ALLOWANCE MAILED Assistant Examiner ISSUE FEE Date Paid Primary Examiner Primary Examiner Application Examiner WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title Sections 122, 181 and 368, Possession outside the U.S. Patent & Tradema	erified and Acknowle	edged Examiners's inti	als			1103326-0538
TOTAL CLAIMS ALLOWED Total Claims Print Cla Q.G Print Cla Date Paid Primary Examiner Primary Examiner Primary Examiner Application Examiner WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title Sections 122, 181 and 368, Possession outside the U.S. Patent & Tradema	TLE : Crystallin	e form of omepraz	ole			U.S.DEPT. OF COMM./PAT.& TM-PTO-436L(Rev. 12-9
Primary Examiner Primary Examiner Primary Examiner Primary Examiner Primary Examiner Application Examiner WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title Sections 122, 181 and 368, Possession outside the U.S. Patent & Tradema	TICE OF ALLOW	ANCE MAILED		nt Examiner		CLAIMS ALLOWED Total Claims Print Cla O.G
Unauthorized disclosure may be prohibited by the United States Code Tith Sections 122, 181 and 368, Possession outside the U.S. Patent & Traderra	ount Due	Pate Paid	PR	4 4		Sheets Drug: Figs.Drug: Pr
	0	ISCLAMER	Unauthor Sections	rized disclosure (122, 181 and 36	may be p	rohibited by the United States Code Titlesion outside the U.S. Patent & Tradema